Published in final edited form as:

Neurosci Lett. 2010 January 22; 469(2): 265–267. doi:10.1016/j.neulet.2009.12.011.

***CALHM1* P86L polymorphism does not alter amyloid- β or tau in cerebrospinal fluid**

Vilmantas Giedraitis^a, Anna Glaser^a, Timo Sarajärvi^b, RoseMarie Brundin^a, Malin Degerman Gunnarsson^a, Brit-Maren Schjeide^{c,d}, Rudolph E. Tanzi^d, Seppo Helisalmi^b, Tuula Pirttilä^b, Lena Kilander^a, Lars Lannfelt^a, Hilikka Soininen^b, Lars Bertram^{c,d}, Martin Ingelsson^a, and Mikko Hiltunen^{b,*}

^a Uppsala University, Department of Public Health/Geriatrics, Rudbeck Laboratory, Uppsala, Sweden ^b University and University Hospital of Kuopio, Department of Neurology, Kuopio, Finland

^c Neuropsychiatric Genetics Group, Department of Vertebrate Genomics, Max-Planck Institute for Molecular Genetics, Berlin, Germany ^d Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease (MIND), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA

Abstract

Recently, the *P86L* alteration in *CALHM1* (calcium homeostasis modulator-1) was reported to be associated with Alzheimer's disease (AD). Moreover, the risk allele increased amyloid- β (A β) levels in conditioned media from cultured cells. Therefore, we hypothesized that *CALHM1* *P86L* may modulate A β or tau levels in cerebrospinal fluid (CSF). Nearly 200 individuals with AD or other cognitive disorders were included for CSF analysis and *CALHM1* genotyping. No significant differences in CSF levels of A β 42, tau or phospho-tau were found across the various *CALHM1* genotypes. In conclusion, we found no evidence that *CALHM1* *P86L* is associated with altered CSF levels of the investigated AD biomarkers.

Keywords

CALHM1; Calcium homeostasis modulator-1; Amyloid- β ; Alzheimer's disease; Cerebrospinal fluid; Biomarker; Total tau; Phospho-tau; Genotyping SNP

Alzheimer's disease (AD) is a genetically heterogeneous disorder believed to be initiated by the deposition of amyloid- β (A β) peptides in the brain. Apart from rare familial early-onset forms caused by mutations in the genes for amyloid precursor protein (*APP*), presenilin 1 (*PSEN1*) and presenilin 2 (*PSEN2*) several risk genes have been suggested, of which only a fraction show consistent results upon meta-analysis [1]. Of these, only the apolipoprotein E (*APOE*) has been established to modulate the risk for AD. Carriers of one *APOE* ϵ 4 allele have a 3–4 times increased disease risk whereas *APOE* ϵ 4 homozygotes are 10–15 times more susceptible to AD [10].

The pathogenic mechanisms underlying the association between *APOE* ϵ 4 and AD risk are only partly understood, but several lines of evidence suggest that the ϵ 4 allele increases the deposition of A β , particularly of more aggregation-prone A β 42 peptides. Consistent with

*Corresponding author at: Department of Neurology, University of Kuopio, P.O. Box 1627, 70211 Kuopio, Finland. Tel.: +358 40 355 2014; fax: +358 17 162048. mhiltune@uku.fi (M. Hiltunen).

this, AD patients with the *APOE* ϵ 4 allele have increased levels of aggregated A β in brain (as shown by PET-PIB imaging) [6] along with decreased levels of A β 42 in cerebrospinal fluid (CSF) [4,5,11,12]. The cause for decreased CSF A β 42 in AD is not completely understood, although it has been assumed to reflect the increased deposition of A β plaques in the diseased brain.

Recently, a novel gene on chromosome 10 (10q24.33) was reported to modulate the risk for late-onset sporadic AD [3]. In that study, several independent case-control cohorts were genotyped for a Pro to Leu alteration at codon 86 (*P86L*; rs2986017) in the gene for calcium homeostasis modulator-1 (*CALHM1*), a transmembrane glycoprotein. Heterozygotes for the leucine-allele were found to have approximately 30% increased risk for AD, whereas homozygotes appeared to have an almost 80% risk increase [3] as compared to proline homozygotes. Much like most other proposed genetic associations in AD, the relevance of this potential risk effect remains to be investigated, as no association with disease risk was found in at least three independent follow-up studies [2,8,9]. According to the biochemical assessments, *CALHM1 P86L* risk allele was found to affect APP processing in a calcium-dependent fashion, and to increase A β levels in the conditioned media of cultured Chinese hamster ovary (CHO) cells [3]. This was attributed to an impairment of the normal function of *CALHM1*, which would result in an increase of extracellular levels of A β . Collectively, these data suggest that *CALHM1* may act as an important regulator of A β metabolism also in the human brain.

In this study, we investigated whether or not the proposed *CALHM1 P86L* risk allele affects CSF levels of A β 42, total tau and phospho-tau in patients with AD or other cognitive conditions. CSF from a total of 186 individuals was analyzed and all cases were genotyped for *CALHM1 P86L*, allowing us to investigate the influence of *CALHM1 P86L* on CSF biomarker levels.

A total of 70 (age $\pm$ SD 66.8 $\pm$ 8.2 years, 48% females) Swedish cases, recruited from the Memory Disorder Unit at Uppsala University Hospital, underwent lumbar puncture as part of clinical dementia investigation. The *CALHM1* genotype was successfully determined on 67 of the cases. Of these, 18 patients were diagnosed with probable AD based on NINCDS-ADRDA criteria [7]. The remaining 49 patients were diagnosed with other cognitive diagnoses, such as mild cognitive impairment ($n = 34$), non-specified dementia ($n = 1$), subjective memory disturbance ($n = 10$), and frontotemporal dementia ($n = 4$). Moreover, 119 AD cases (age-at-onset 70.5 $\pm$ 7.1 years, 72% females) from eastern Finland underwent lumbar puncture as part of a dementia investigation at the Department of Neurology of Kuopio University Hospital. All patients fulfilled the NINCDS-ADRDA criteria for probable AD [7]. Informed consent was obtained from all Swedish and Finnish subjects and the study was approved by the Regional Ethical Committee in Uppsala and The Ethics Committee of Kuopio University Hospital/Kuopio University, respectively.

Genotypes for the *CALHM1 P86L* (rs2986017) variant were generated as previously described [2], either by single-base extension followed by high-efficiency fluorescence polarization (HEFP) detection, or by direct sequencing. Genotyping efficiency was 96%, and the error rate below 0.2%. The Swedish and Finnish CSF samples were analyzed for A β 42 (INNOTEST[®] β -AMYLOID₍₁₋₄₂₎, Innogenetics, Ghent, Belgium). Moreover, the samples were also analyzed for total tau (t-tau, INNOTEST hTAU Ag, Innogenetics), and tau phosphorylated at Thr¹⁸¹ (p-tau, INNOTEST PHOSPHO-TAU_(181P), Innogenetics).

Kruskal–Wallis ANOVA followed by a Mann–Whitney *U* test was used to investigate possible differences in CSF A β 42, tau or p-tau between subjects with the different *CALHM1* genotypes. In order to combine data from Swedish and Finnish samples, marker levels were

normalized based on the mean concentration of each biomarker in the CC genotype carriers. Power analysis indicated a power of 0.84 to detect a 1.2-fold increase in A β 42 levels between the *CALHM1* CC and CT genotypes. However, due to the lower number of samples and higher variation power to detect 1.2-fold increase in tau and p-tau was only 0.36 and 0.47, respectively. All statistical analyses were performed by the Statistica software (StatSoft Inc. Tulsa, OK, USA).

When analyzing the Swedish and Finnish cohorts separately, CSF levels of A β 42, total tau, and p-tau did not differ with respect to the *CALHM1* genotype (Table 1). Although absolute CSF A β 42, tau, and p-tau concentrations were very similar between the Swedish and Finnish groups (Fig. 1), their respective levels were normalized within each cohort, allowing a combined analyses of samples. When analyzing the combined Swedish–Finnish sample set, no significant differences were detected between heterozygous and homozygous carriers of the “risk allele” (leucine or T) as compared to subjects homozygous for the “wild-type” (proline or C) allele. Finally, no differences were found when analyzing the AD and non-AD subgroups separately.

Based on recently described findings [3], we investigated whether CSF levels of A β 42 are affected between carriers and non-carriers of the proposed AD risk allele (*P86L*) in *CALHM1*. In addition, we also analyzed total and phosphorylated tau levels, since both of these biomarkers are known to negatively correlate with CSF A β levels. However, the results should be interpreted cautiously, because of the low sample numbers and high inter-individual variations in biomarker levels. When analyzing CSF A β 42, t-tau and p-tau from Swedish and Finnish patients, we did not detect any significant differences with respect to the *CALHM1* genotype. Furthermore, separate subgroup analyses on AD ($n = 18$) and non-AD ($n = 48$) cases in the Swedish cohort also failed to show any correlation between the *CALHM1* genotype status and the investigated CSF biomarkers. In conclusion, we did not find any evidence that the *CALHM1 P86L* variation affects levels of A β and tau in CSF from cases with AD or other cognitive disorders.

Acknowledgments

Financial support for this project was provided by the Swedish Research Council, the Swedish Brain Foundation, the Swedish Alzheimer Foundation, the EVO Research Fund of Helsinki University Hospital, the Health Research Council of the Academy of Finland, EVO grant 5772708 of Kuopio University Hospital, The Nordic Centre of Excellence of Neurodegeneration, the University of Kuopio Graduate School of Molecular Medicine and the Cure Alzheimer's Fund.

References

1. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. *Nature Genetics* 2007;39:17–23. [PubMed: 17192785]
2. Bertram L, Schjeide BM, Hooli B, Mullin K, Hiltunen M, Soininen H, Ingelsson M, Lannfelt L, Blacker D, Tanzi RE. No association between *CALHM1* and Alzheimer's disease risk. *Cell* 2008;135:993–994. (author reply 994–996). [PubMed: 19070563]
3. Dreses-Werringloer U, Lambert J, Vingtdeux V, Zhao H, Vais H, Siebert A, Jain A, Koppel J, Rovelet-Lecrux A, Hannequin D, Pasquier F, Galimberti D, Scarpini E, Mann D, Lendon C, Campion D, Amouyel P, Davies P, Fosskett J, Campagne F, Marambaud P. A polymorphism in *CALHM1* influences Ca²⁺ homeostasis, Abeta levels, and Alzheimer's disease risk. *Cell* 2008;133:1149–1161. [PubMed: 18585350]
4. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease

- and relation to apolipoprotein E genotype. *Archives of Neurology* 1998;55:937–945. [PubMed: 9678311]
5. Johansson A, Katzov H, Zetterberg H, Feuk L, Johansson B, Bogdanovic N, Andreassen N, Lenhard B, Brookes A, Pedersen N, Blennow K, Prince J. Variants of CYP46A1 may interact with age and APOE to influence A β 42 levels in Alzheimer's disease. *Human Genetics* 2004;114:581–587. [PubMed: 15034781]
 6. Kempainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, Oikonen V, Kailajarvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. *Neurology* 2007;68:1603–1606. [PubMed: 17485647]
 7. McKhann G, Drachman D, Folstein M. Clinical diagnosis of Alzheimer's disease: report of NINCDS-ADRDA Work Group under the auspices of department of health and human services task forces on Alzheimer's disease. *Neurology* 1984;34:939–944. [PubMed: 6610841]
 8. Minster RL, Demirci FY, DeKosky ST, Kamboh MI. No association between CALHM1 variation and risk of Alzheimer disease. *Human Mutation* 2009;30:E566–E569. [PubMed: 19191331]
 9. Sleegers K, Brouwers N, Bettens K, Engelborghs S, van Miegroet H, De Deyn PP, Van Broeckhoven C. No association between CALHM1 and risk for Alzheimer dementia in a Belgian population. *Human Mutation* 2009;30:E570–E574. [PubMed: 19191332]
 10. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to β -amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proceedings of the National Academy of Sciences of the United States of America* 1993;90:1977–1981. [PubMed: 8446617]
 11. Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. *Biological Psychiatry* 2004;56:670–676. [PubMed: 15522251]
 12. Tapiola T, Pirttila T, Mehta PD, Alafuzoff I, Lehtovirta M, Soininen H. Relationship between apoE genotype and CSF beta-amyloid (1–42) and tau in patients with probable and definite Alzheimer's disease. *Neurobiology of Aging* 2000;21:735–740. [PubMed: 11016543]

Fig. 1. Normalized CSF levels of Aβ42, total tau and p-tau with respect to the *CALHM1* P86L genotypes in Swedish and Finnish sample sets. Horizontal line shows median level of the combined sample set.

Table 1

Cerebrospinal fluid (CSF) levels of A β 42, total-tau (t-tau) and phospho-tau (p-tau) among Swedish and Finnish subjects with different *CALHM1 P86L* genotypes (rs2986017).

	rs2986017 genotype			Total
	CC	CT	TT	
Swedish				
<i>n</i> (%)	37 (55.2)	25 (37.3)	5 (7.5)	67
t-tau [ng/ml] (SD)	607.3 (440.8)	457.2 (219.3)	498.0 (182.0)	543.1 (361.6)
p-tau [ng/ml] (SD)	94.2 (61.1)	72.2 (33.5)	63.8 (17.5)	83.7 (51.0)
Aβ42 [ng/ml] (SD)	469.4 (242.3)	519.2 (240.2)	530.0 (218.2)	492.5 (237.8)
Finnish				
<i>n</i> (%) ^a	77 (64.7)	38 (31.9)	4 (3.4)	119
t-tau [ng/ml] (SD)	488.2 (253.5)	627.4 (395.5)	457.0 (0)	531.6 (310.7)
p-tau [ng/ml] (SD)	66.8 (21.7)	77.8 (45.2)	67.0 (0)	71.0 (31.5)
Aβ42 [ng/ml] (SD)	485.6 (191.7)	453.3 (152.3)	552.2 (124.5)	477.0 (177.5)

^aNumber of available samples for t-tau and p-tau measurements: CC = 28, CT = 16, and TT = 1.